Characteristics | Patients with pSS | Controls |
---|---|---|
No. subjects | 22 | 20 |
Sex, female/male | 19/3 | 14/6 |
Age, yrs, median (range) | 51 (43–61) | 57.5 (44–71) |
Disease duration, yrs, median (range) | 6.5 (2–15) | NA |
Duration of sicca symptoms, median (range) | 8.9 (2–23) | NA |
ESSDAI score, median (range) | 9.5 (3–19) | NA |
Anti-Ro/SS-A antibodies +, n (%) | 6 (27.0) | NA |
Anti-La/SS-B antibodies +, n (%) | 5 (23.0) | NA |
ANA, n (%) | 12 (0.51) | NA |
RF+, n (%) | 15 (68.1) | NA |
ESR, mm, median (range) | 29 (0.4–11.7) | NA |
CRP, mg/l, mean (SD) | 3.78 (0.4–11.7) | NA |
Complement C3, g/l, mean (SD) | 1.19 (0.26) | NA |
Complement C4, g/l, mean (SD) | 0.28 (0.048) | NA |
Haptoglobin, g/l, median (range) | 1.43 (0.5–2.9) | NA |
Serum albumins, g/l, mean (SD) | 47.17 (4.01) | NA |
Serum gamma globulins, mean (SD) | 11.48 (6.22) | NA |
IgG, g/l, median (range) | 11.61 (8.1–15.12) | NA |
IgA, g/l, median (range) | 2.5 (1.01–3.85) | NA |
IgM, g/l, median (range) | 2.5 (0.45–4.51) | NA |
IgE, g/l, median (range) n (%) | 465.5 (7.55–666) | NA |
PSL, ng 5HT/109 platelets, mean (SD) | 353.1 (158.06) | NA |
MSG biopsies focus score ≥ 1 | 16 | NA |
MSG biopsy grade 3 | 11 (50.0) | NA |
MSG biopsy grade 4 | 5 (23.0) | NA |
ESSDAI: European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index; ESR: erythrocyte sedimentation rate; Ig: serum immunoglobulin; MSG: minor salivary gland; NA: not applicable; ANA: antinuclear antibodies; RF: rheumatoid factor; CRP: C-reactive protein; PSL: platelet serotonin level.